Showing 11,741 - 11,760 results of 41,940 for search '(( 50 ((ng decrease) OR (((nn decrease) OR (a decrease)))) ) OR ( a point decrease ))', query time: 0.85s Refine Results
  1. 11741
  2. 11742

    Autoantibodies as diagnostic markers and potential drivers of inflammation in ulcerative colitis by Henrika Jodeleit (4722312)

    Published 2020
    “…Furthermore, levels of anti-CD99 antibodies increased (Control: 398 ± 323; mean MFI ± sd; Ethanol + PBS: 358 ±316; Ethanol + CD99: 1363 ± 1336; Control versus Ethanol + CD99: p = 0.03). In a highly inflammatory environment, frequencies of pro-inflammatory M1 monocytes (CD14+ CD64+: unchallenged 8.09±4.72; challenged 14.2±8.62; p = 0.07; CD14+ CD1a+: unchallenged 16.29 ±6.97; challenged 43.81±14.4, p = 0.0003) increased and levels of autoantibodies in serum decreased in the NSG-UC mouse model. …”
  3. 11743
  4. 11744
  5. 11745

    Meta-analyses of the association of <i>G6PC2</i> allele variants with elevated fasting glucose and type 2 diabetes by Yuanyuan Shi (563992)

    Published 2017
    “…Per increment of G allele at rs560887 and A allele at rs573225 resulted in a FG 0.070 mmol/l and 0.075 mmol/l higher (ß (95% CI) = 0.070 (0.060, 0.079), <i>p</i> = 4.635e-50 and 0.075 (0.065, 0.085), <i>p</i> = 5.856e-48, respectively). …”
  6. 11746

    Assessment of Membrane Fluidity Fluctuations during Cellular Development Reveals Time and Cell Type Specificity - Fig 2 by Pakiza Noutsi (3160734)

    Published 2016
    “…At 72 h GP reached maximum values (0.45) ± SEM and decreased to 0.25 ± SEM after 92 h. 10 cells were analyzed for each time point for statistical significance. d) Histograms of GP distributions among L6 cells at 12 h, 48 h, 72 h and 92 h respectively. …”
  7. 11747
  8. 11748

    Discovery of Novel Pyrimidine-Based Capsid Assembly Modulators as Potent Anti-HBV Agents by WooChan Kim (10690503)

    Published 2021
    “…Moreover, treatment with compound <b>23h</b> for 5 weeks significantly decreased serum levels of HBV DNA levels (3.35 log reduction) in a human liver-chimeric uPA/SCID mouse model, and these effects were significantly increased when <b>23h</b> was combined with tenofovir, a nucleotide analogue inhibitor of reverse transcriptase used for the treatment of HBV infection.…”
  9. 11749

    Isoindolin-1-ones Fused to Barbiturates: From Design and Molecular Docking to Synthesis and Urease Inhibitory Evaluation by Houman Kazemzadeh (12742141)

    Published 2022
    “…In vitro urease inhibitory results indicated that all the compounds had higher inhibitory activity than the standard inhibitor, thiourea, and compound <b>5b</b> proved to be the most potent inhibitor (IC<sub>50</sub> = 0.82 ± 0.03 μM). A molecular docking study was performed to understand the interaction between compounds <b>5a–n</b> and Jack bean urease enzyme. …”
  10. 11750

    GFP+ NPC Implant Apoptosis. Implants were sectioned and immunostained for the early effector caspase, cleaved caspase-3 (red, GFP = green, DAPI = blue) and area of fluorescence rel... by Cicely Williams (291856)

    Published 2013
    “…<p>This initially higher rate of apoptosis significantly decreased by day 5 (0.036±0.050, p = 0.0063) to a rate comparable to that of the NPC∶BEC implants. …”
  11. 11751

    Study on the Effects of Nonelectrolyte Additives on the Phase, Thermodynamics, and Structural Changes in Micelles of Silicone Surfactants in Aqueous Solutions from Surface Activity... by Saurabh S. Soni (1708960)

    Published 2003
    “…The influence of given additive on the micellization of silicone surfactants was monitored from the changes in the free energy of micellization values for the surfactant solutions in water and water + additives. The cloud points and the critical micelle concentration values for the surfactant solutions were found to be decreased in the presence of the selected three additives. …”
  12. 11752

    <i>In silico</i> screening identifies doxazosin as a novel agonist for EphA2 receptor. by Aaron Petty (143170)

    Published 2012
    “…Note decreasing amount of EphA2 following ephrin-A1 and doxazosin treatment. …”
  13. 11753
  14. 11754

    Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study by David N. Franz (822882)

    Published 2016
    “…Everolimus was initiated at a dose (4.5 mg/m<sup>2</sup>/day) titrated to a target blood trough of 5–15 ng/mL. …”
  15. 11755
  16. 11756
  17. 11757
  18. 11758
  19. 11759
  20. 11760